SCNX:NASDAQScienture Holdings, Inc. Analysis

Technical snapshot: SCNX trades at $0.40, barely above its 20‑day SMA (0.397) and 50‑day SMA (0.393) but far under the 200‑day SMA (0.638). RSI sits at a neutral 51, while the MACD histogram is negative and the signal line is bearish. Volume is on a downtrend, beta is high at 2.89 and 30‑day volatility spikes at 68%, with a historical max drawdown of -90%, all pointing to a short‑term bias toward caution.
Fundamental picture: The company posted $477 k in revenue with a modest 4.5% growth and an impressive 80.5% gross margin, yet operating margin is a deep -62% and EBITDA is a $15.3 M loss. Cash flow is negative (operating cash flow -$13.3 M, free cash flow -$0.8 M). The stock trades at a price‑to‑book of 0.24 (book value $1.645 per share) and has a target price of $1.50, implying a potential upside of roughly 275%, but the lack of earnings and cash burn raise serious concerns.
Recent catalysts: Q1‑2026 results highlight revenue growth and gross‑margin expansion, and the company announced proceeds will fund commercialization of the FDA‑approved oral suspension Arbli™ and other pipeline candidates. While these developments could spark upside, the early‑stage nature of the products and ongoing cash deficits keep risk elevated.